Hemophilia A

← Back to Index(🩸 Hematology and Oncology)

Introduction And Genetics

X-linked recessive bleeding disorder.
Results from decreased blood levels of functional procoagulant Factor VIII (FVIII).
Incidence roughly 1 per 5000 males.
Constitutes 80-85% of all hemophilia cases.
F8 gene located near terminus of long arm of X chromosome.
Spontaneous de novo mutations account for one-third of cases.
Intron 22 inversion mutation identifiable in 45-50% of severe cases.
Female carriers generally asymptomatic.
Symptomatic female carriers occur secondary to skewed lyonization or Turner syndrome, exhibiting factor levels <40%.

Pathophysiology Of Hemorrhage

Activated FVIII acts as essential cofactor.
Participates in intrinsic tenase complex with activated Factor IX, calcium, and phospholipids on platelet surfaces.
Complex drives sustained proteolytic activation of Factor X.
FVIII deficiency yields insufficient thrombin generation.
Normal platelet plug forms initially but lacks cross-linked fibrin stabilization.
Results in delayed, ineffectual, highly friable clot formation.
Rebleeding occurs with physiologic thrombolysis or minimal subsequent trauma.

Classification By Severity

Severity Phenotype	Factor Activity Level	Clinical Bleeding Characteristics	Proportion Of Cases
Severe	<1%	Frequent, spontaneous hemorrhage; spontaneous hemarthroses; deep soft tissue bleeds	70%
Moderate	1-5%	Gross bleeding post mild-to-moderate trauma; rare spontaneous bleeds	15%
Mild	5-40%	Severe hemorrhage only post moderate-to-severe trauma or surgery; often delayed diagnosis	15%

Clinical Manifestations

Neonatal Presentation

FVIII does not cross placenta; bleeding symptoms possible at birth.
Intracranial hemorrhage occurs in 1-4% of neonates, mostly birth trauma-related.
Post-circumcision bleeding absent in 35% of severe and 70% of non-severe cases.
Diagnosis frequently missed in newborn period without positive family history.

Post-Neonatal And Childhood Presentation

Symptoms manifest when infant begins cruising or walking.
Easy bruising, intramuscular hematomas, frequent joint bleeds.
Prolonged bleeding from minor oral lacerations (torn frenulum).

Common Sites Of Hemorrhage

Hemarthrosis: Hallmark manifestation. Ankles affected earliest, followed by knees and elbows.
Target Joints: Recurrent bleeds into same joint induces synovial changes, precipitating further bleeds.
Intramuscular Hematomas: High-risk locations include iliopsoas, calf, and forearm. Carry risk of compartment syndrome and nerve compression.
Life-Threatening Hemorrhage: Intracranial, intraspinal, retropharyngeal, and retroperitoneal spaces. Exsanguination risk high without prompt factor replacement.
Mucosal Bleeding: Epistaxis, dental extractions.

Diagnostic Evaluation

Screening Coagulation Assays

Activated Partial Thromboplastin Time (aPTT): Markedly prolonged. Usually 2-3 times upper normal limit in severe disease. May remain normal in mild disease depending on reagent sensitivity.
Prothrombin Time (PT): Normal.
Platelet Count And Bleeding Time: Normal.
Mixing Studies: aPTT corrects completely upon 1:1 mixing with normal pooled plasma, confirming factor deficiency rather than acquired inhibitor.

Confirmatory Assays

Specific quantitative assay for FVIII activity required for definitive diagnosis.
Expressed in International Units (IU); 1 IU equals factor amount in 1 mL normal plasma (100% activity).
Neonatal FVIII levels artificially elevated secondary to acute-phase birth stress.
Borderline low-normal levels in neonates necessitate repeat testing at 6 months of age.

Prenatal And Carrier Testing

Chorionic villus sampling performed at 10-12 weeks gestation.
Amniocentesis performed after 15 weeks gestation.
Fetal blood sampling via cordocentesis feasible at 18-20 weeks.
Carrier detection utilizes targeted mutation analysis.
FVIII/vWF:Ag ratio <1.0 detects 80% of carriers with 95% accuracy.

Management Strategies

Principles Of Factor Replacement Therapy

Intravenous replacement of deficient FVIII represents mainstay of therapy.
Pharmacokinetics: 1 IU/kg raises plasma FVIII level by 2%. Half-life 8-12 hours.
Dosing Formula: Dose (IU) = Desired Rise (%) × Body Weight (kg) × 0.5.

Factor Product Classes

Plasma-Derived Concentrates: Undergo rigorous viral inactivation (solvent-detergent, pasteurization, nanofiltration).
Recombinant Concentrates: Treatment of choice for previously untreated patients; eliminates bloodborne pathogen risk.
Extended Half-Life (EHL) Products: FVIII protein fused to Fc portion of IgG1 or PEGylated. Reduces clearance; facilitates less frequent prophylactic dosing (every 3-5 days).

Acute Hemorrhage Management (On-Demand Therapy)

Hemorrhage Type	Target FVIII Level	Recommended FVIII Dosing	Adjunct Interventions
Hemarthrosis	30-50%	50-60 IU/kg day 1; 20 IU/kg every other day	Rest, cold compress, immobilization.
Intramuscular	40-50%	50 IU/kg initially; 20 IU/kg every other day	Monitor for compartment syndrome.
Oral/Dental	50%	20 IU/kg single dose	Antifibrinolytics critical.
Life-Threatening/CNS	100%	50-75 IU/kg bolus; maintain trough >50% for 5-7 days	Hospitalization; immediate infusion prior to imaging.

Prophylaxis Therapy

Standard of care for children with severe hemophilia A.
Objective: Convert severe phenotype to moderate phenotype.
Maintains trough factor levels >1-2%.
Prevents spontaneous hemorrhages; preserves joint integrity.
Standard Regimens: Intravenous administration 3-4 times weekly for standard products. Frequency reduced with extended half-life products.
Often requires surgical insertion of central venous access devices in young children; carries inherent infection and thrombosis risks.

Novel Non-Factor And Gene Therapies

Emicizumab: Bispecific humanized monoclonal antibody bridging FIXa and FXa. Mimics FVIIIa cofactor activity. Administered subcutaneously weekly to monthly. Highly effective for routine prophylaxis regardless of inhibitor status. Shortens aPTT artificially.
Efanesoctocog Alfa: Modified extended half-life recombinant FVIII decoupled from endogenous von Willebrand factor.
Fitusiran: Small interfering RNA molecule inhibiting antithrombin synthesis. Rebalances hemostasis.
Gene Therapy (Valoctocogene Roxaparvovec): Utilizes adeno-associated viral (AAV) vectors to deliver FVIII gene. Restores endogenous factor production.

Ancillary Therapies

Desmopressin (DDAVP): Stimulates endogenous endothelial release of FVIII and vWF. Increases baseline FVIII twofold to fivefold. Indicated for mild hemophilia A. Dose: 0.3 μg/kg intravenously or 150-300 μg intranasal spray (Stimate). Contraindicated in children <2 years due to severe hyponatremic seizure risk. Tachyphylaxis occurs after 4-5 consecutive days.
Antifibrinolytic Agents: Epsilon-aminocaproic acid (EACA) or tranexamic acid. Inhibit plasminogen activation. Efficacious for mucosal, oral, and epistaxis hemorrhage. Contraindicated in urinary tract hemorrhage due to intrarenal clot formation risk.

Complications

Inhibitor Development

Represents most severe complication of modern replacement therapy.
Neutralizing IgG alloantibodies target exogenous FVIII.
Occurs in 20-30% of severe Hemophilia A patients.
Risk factors: Large gene deletions, African-American ethnicity, early intensive factor expo
Results from decreased blood levels of functional procoagulansure (trauma, surgery).
Quantification: Bethesda Assay. 1 Bethesda Unit (BU) neutralizes 1 IU/mL of factor activity.

Management Of Inhibitors

Low Responders (<5 BU): Exhibit no anamnestic titer rise upon rechallenge. Managed with high-dose specific FVIII concentrates to overwhelm circulating inhibitor.
High Responders (>5 BU): Exhibit rapid anamnestic response. Require bypassing agents for hemostatic control.
- Activated Prothrombin Complex Concentrate (aPCC / FEIBA): Contains FVIIa, FXa, prothrombin. Dose: 75-100 U/kg q8-12h. Thrombogenic risk at high/prolonged doses.
- Recombinant FVIIa (NovoSeven): Bypasses FVIII requirement. Dose: 90 μg/kg q2h.
Immune Tolerance Induction (ITI): Frequent, high-dose administration of FVIII concentrate (e.g., 200 IU/kg/day). Aims to induce immunologic tolerance and eradicate inhibitor. Success rate approximately 70% in Hemophilia A.
Immunosuppression: Rituximab (anti-CD20 antibody) utilized in ITI failure.
Plasmapheresis: Extracorporeal immunoadsorption rapidly reduces severe acute inhibitor titers in life-threatening bleeding situations.

Hemophilic Arthropathy

Chronic, debilitating joint destruction stemming from recurrent hemarthroses.
Intra-articular hemorrhage triggers macrophage proliferation via heme iron.
Synovial inflammation ensues.
Synovium thickens, develops frond-like projections susceptible to mechanical pinching and recurrent bleeding (target joint cycle).
Culminates in articular cartilage erosion, raw bone exposure, and eventual joint fusion.

Transfusion-Transmitted Infections

Historically high transmission rates of Hepatitis B, Hepatitis C, and HIV via non-inactivated plasma products.
Modern risk virtually eliminated via stringent donor nucleic acid testing, solvent-detergent viral inactivation, nanofiltration, and widespread utilization of recombinant factors.